ABVC BioPharma Inc. (ABVC)
ABVC BioPharma Statistics
Share Statistics
ABVC BioPharma has 15.78M shares outstanding. The number of shares has increased by 7.66% in one year.
| Shares Outstanding | 15.78M |
| Shares Change (YoY) | 7.66% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.78% |
| Shares Floating | 11.24M |
| Failed to Deliver (FTD) Shares | 2.95K |
| FTD / Avg. Volume | 0.43% |
Short Selling Information
The latest short interest is 288.31K, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 288.31K |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 1.79 |
Valuation Ratios
The PE ratio is -1.36 and the forward PE ratio is 0.67. ABVC BioPharma's PEG ratio is 0.02.
| PE Ratio | -1.36 |
| Forward PE | 0.67 |
| PS Ratio | 14.38 |
| Forward PS | 0.3 |
| PB Ratio | 5.97 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ABVC BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33, with a Debt / Equity ratio of 1.98.
| Current Ratio | 0.33 |
| Quick Ratio | 0.33 |
| Debt / Equity | 1.98 |
| Debt / EBITDA | 50.14 |
| Debt / FCF | - |
| Interest Coverage | -0.06 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $31.8K |
| Profits Per Employee | $-335.6K |
| Employee Count | 16 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.14% in the last 52 weeks. The beta is 0.33, so ABVC BioPharma's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -42.14% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 0.65 |
| Relative Strength Index (RSI) | 53.13 |
| Average Volume (20 Days) | 679.95K |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of 508.83K and earned -5.37M in profits. Earnings per share was -0.43.
| Revenue | 508.83K |
| Gross Profit | 508.83K |
| Operating Income | 48.48K |
| Net Income | -5.37M |
| EBITDA | 48.48K |
| EBIT | -6.2M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
The company has 248.38K in cash and 2.43M in debt, giving a net cash position of -2.18M.
| Cash & Cash Equivalents | 248.38K |
| Total Debt | 2.43M |
| Net Cash | -2.18M |
| Retained Earnings | -68.95M |
| Total Assets | 14.46M |
| Working Capital | -4.17M |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0.
| Operating Cash Flow | 0 |
| Capital Expenditures | 0 |
| Free Cash Flow | 0 |
| FCF Per Share | 0 |
Margins
Gross margin is 100%, with operating and profit margins of 9.53% and -1055.29%.
| Gross Margin | 100% |
| Operating Margin | 9.53% |
| Pretax Margin | -1055.29% |
| Profit Margin | -1055.29% |
| EBITDA Margin | 9.53% |
| EBIT Margin | 9.53% |
| FCF Margin | n/a |
Dividends & Yields
ABVC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ABVC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 25, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 25, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -7.49 |
| Piotroski F-Score | 3 |